Allopregnanolone reduces immobility in the forced swimming test and increases the firing rate of lateral septal neurons through actions on the GABAA receptor in the rat

Journal of Psychopharmacology
Juan Francisco Rodríguez-LandaMargarita Saavedra

Abstract

Since allopregnanolone reduces the total time of immobility in rats submitted to the forced swimming test, we decided to explore whether this neuroactive steroid shares other antidepressant-like actions, such as increasing the neuronal firing rate in the lateral septal nucleus (LSN). In order to discard the influence of the oestrous cycle on immobility and on the firing rate of LSN neurons, all Wistar rats used in the study underwent ovariectomy before treatments. A group of rats received different doses of allopregnanolone (0.5, 1.0, 2.0 and 3.0 mg/kg, i.p.) 1 hour before being forced to swim in order to identify the minimum effective dose diminishing immobility. None of the tested doses of allopregnanolone produced significant changes in motor activity in the open-field test. The minimum dose of allopregnanolone producing a significant reduction in the total time of immobility (p<0.05) against the vehicle was 1.0 mg/kg, while 2.0 mg/kg and above also increased the latency to the first period of immobility (p<0.05). The minimum effective dose of allopregnanolone reducing immobility in the forced swimming test (1.0 mg/kg) significantly (p <0.05) produced a higher (twofold) neuronal firing rate in LSN neurons, but did not produc...Continue Reading

References

Feb 15, 1978·European Journal of Pharmacology·R D PorsoltM Jalfre
May 25, 1991·Proceedings of the National Academy of Sciences of the United States of America·R H PurdyS M Paul
May 3, 1991·Brain Research·E ThomasC E Strickland
Oct 1, 1990·Physiology & Behavior·C M ContrerasM A Guzmán-Sáenz
Nov 1, 1989·Physiology & Behavior·C M ContrerasM L Marván
Dec 21, 1993·European Journal of Pharmacology·A CeciF Borsini
Jun 1, 1993·Physiology & Behavior·E YadinC E Strickland
Jul 25, 1995·European Journal of Pharmacology·A Fernández-Guasti, O Picazo
Dec 29, 1995·Annals of the New York Academy of Sciences·A L MorrowS M Paul
Oct 29, 1996·Proceedings of the National Academy of Sciences of the United States of America·D P UzunovA Guidotti
Jan 1, 1997·Naunyn-Schmiedeberg's Archives of Pharmacology·N HaddjeriC de Montigny
Nov 14, 1997·Obstetrics and Gynecology·A J RapkinV B Mahesh
Apr 18, 1998·Proceedings of the National Academy of Sciences of the United States of America·V UzunovaA Guidotti
May 20, 1998·Pharmacology, Biochemistry, and Behavior·B Zimmerberg, L G Blaskey
Nov 26, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·C M ContrerasM Saavedra
Nov 11, 1999·Proceedings of the National Academy of Sciences of the United States of America·L D Griffin, S H Mellon
Nov 26, 1999·Archives of Medical Research·L Martínez-MotaM Saavedra
Feb 16, 2000·Psychoneuroendocrinology·L Martínez-MotaA Fernández-Guasti
Mar 15, 2000·Physiology & Behavior·C M ContrerasL Martínez-Mota
Dec 13, 2000·Pharmacology, Biochemistry, and Behavior·R T KhistiS P Jain
Oct 16, 2001·International Review of Neurobiology·M L BarbacciaG Biggio
Oct 16, 2001·International Review of Neurobiology·L D GriffinS H Mellon
Aug 3, 2002·The European Journal of Neuroscience·Françoise Rougé-PontPier Vincenzo Piazza
Aug 23, 2002·Behavioural Brain Research·Erika Estrada-CamarenaCarolina López-Rubalcava
Nov 7, 2002·Psychopharmacology·Frank van Broekhoven, Robbert J Verkes
Mar 18, 2003·Journal of Clinical Psychopharmacology·Carrie L Ernst, Joseph F Goldberg
Aug 30, 2003·Expert Opinion on Drug Safety·Prakash S Masand, Sanjay Gupta

❮ Previous
Next ❯

Citations

Oct 16, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Patricia J AllenPerry F Renshaw
Oct 16, 2015·Current Psychiatry Reports·Andrew M Siegel, Sarah B Mathews
Jun 30, 2009·Behavioural Processes·Blandina Bernal-MoralesJonathan Cueto-Escobedo
Sep 21, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Anjana Bali, Amteshwar Singh Jaggi
Sep 6, 2011·Journal of Psychopharmacology·Erika Estrada-CamarenaOfir Picazo
Feb 3, 2018·BioMed Research International·Blandina Bernal-MoralesCarlos M Contreras
Jan 20, 2009·Psychopharmacology·Silvia L CruzCarolina López-Rubalcava
Apr 7, 2018·Scientifica·León Jesús German-PoncianoJuan Francisco Rodríguez-Landa
Mar 21, 2019·International Journal of Food Sciences and Nutrition·Rafael Fernández-DemeneghiSocorro Herrera-Meza
Mar 23, 2017·Molecular Psychiatry·K M J McMurrayA A Palmer
Mar 16, 2018·Journal of Evidence-based Integrative Medicine·Juan Francisco Rodríguez-LandaMiguel Carro-Juárez
Jun 28, 2019·Frontiers in Psychology·Jennifer L GordonLaurie Sykes Tottenham
Mar 28, 2019·Frontiers in Cellular Neuroscience·Manoela V Fogaça, Ronald S Duman
Dec 16, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Juan Francisco Rodríguez-LandaElizabeth Romero-Avendaño
Jun 3, 2021·International Journal of Molecular Sciences·Felipe Borges AlmeidaHelena Maria Tannhauser Barros
May 22, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Shiyi ChenYiping Ye
Apr 26, 2011·Behavioural Brain Research·Christian Roberto Mostalac-PreciadoCarolina López-Rubalcava

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.